Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.
Status:
Withdrawn
Trial end date:
2021-06-14
Target enrollment:
Participant gender:
Summary
This is an exploratory, randomized, subject- and investigator-blinded, placebo-controlled
mode-of-action study to demonstrate the anti-inflammatory effects of fevipiprant compared to
placebo after 12 weeks of treatment in 48 moderate to severe asthma patients with sputum and
blood eosinophilia.